Update on aurora kinase targeted therapeutics in oncology

Aurora Kinase Inhibitor PHA-739358 Suppresses Growth of Hepatocellular Carcinoma In Vitro and in a Xenograft Mouse Model

(2015) Daniel Benten et al.   NEOPLASIA

Aurora-C kinase supports mitotic progression in the absence of Aurora-B

(2011) Scott D. Slattery et al.   CELL CYCLE

Aurora B kinase inhibition in mitosis: Strategies for optimizing the use of Aurora kinase inhibitors such as AT9283

(2011) Jayne Curry et al.   CELL CYCLE

The Aurora B kinase inhibitor AZD1152 sensitizes cancer cells to fractionated irradiation and induces mitotic catastrophe

(2011) Yungan Tao et al.   CELL CYCLE

Efficacy of MK-0457 and in combination with vorinostat against Philadelphia chromosome positive acute lymphoblastic leukemia cells

(2010) Seiichi Okabe et al.   ANNALS OF HEMATOLOGY

Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state

(2010) J. den Hollander et al.   BLOOD

A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma

(2010) G. Gorgun et al.   BLOOD

Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma

(2010) Xiaojing Wang et al.   BRITISH JOURNAL OF HAEMATOLOGY

Preclinical Evaluation of AMG 900, a Novel Potent and Highly Selective Pan-Aurora Kinase Inhibitor with Activity in Taxane-Resistant Tumor Cell Lines

(2010) M. Payton et al.   CANCER RESEARCH

Assessment of the In vivo Antitumor Effects of ENMD-2076, a Novel Multitargeted Kinase Inhibitor, against Primary and Cell Line-Derived Human Colorectal Cancer Xenograft Models

(2010) J. J. Tentler et al.   CLINICAL CANCER RESEARCH

Outcomes for Children and Adolescents With Cancer: Challenges for the Twenty-First Century

(2010) Malcolm A. Smith et al.   JOURNAL OF CLINICAL ONCOLOGY

Antiproliferative effect of Aurora kinase targeting in mesothelioma

(2010) Stefania Crispi et al.   LUNG CANCER

Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer

(2010) Christopher P Gully et al.   Molecular Cancer

MLN8054, an Inhibitor of Aurora A Kinase, Induces Senescence in Human Tumor Cells Both In vitro and In vivo

(2010) J. J. Huck et al.   MOLECULAR CANCER RESEARCH

Phase I Study of the Selective Aurora A Kinase Inhibitor MLN8054 in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Pharmacodynamics

(2010) T. Macarulla et al.   MOLECULAR CANCER THERAPEUTICS

The FLT3 Internal Tandem Duplication Mutation Is a Secondary Target of the Aurora B Kinase Inhibitor AZD1152-HQPA in Acute Myelogenous Leukemia Cells

(2010) M. Grundy et al.   MOLECULAR CANCER THERAPEUTICS

PF-03814735, an Orally Bioavailable Small Molecule Aurora Kinase Inhibitor for Cancer Therapy

(2010) Jitesh P. Jani et al.   MOLECULAR CANCER THERAPEUTICS

MK-5108, a Highly Selective Aurora-A Kinase Inhibitor, Shows Antitumor Activity Alone and in Combination with Docetaxel

(2010) T. Shimomura et al.   MOLECULAR CANCER THERAPEUTICS

Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase

(2010) D. Yang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Biochemical characterization of GSK1070916, a potent and selective inhibitor of Aurora B and Aurora C kinases with an extremely long residence time1

(2009) Kelly Anderson et al.   BIOCHEMICAL JOURNAL

Targets and effectors of the cellular response to aurora kinase inhibitor MK-0457 (VX-680) in imatinib sensitive and resistant chronic myelogenous leukemia

(2009) Nicholas J. Donato et al.   BIOCHEMICAL PHARMACOLOGY

The discovery of the potent aurora inhibitor MK-0457 (VX-680)

(2009) David Bebbington et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma

(2009) D. Hose et al.   BLOOD

Mitotic drivers—inhibitors of the Aurora B Kinase

(2009) Nicholas Keen et al.   CANCER AND METASTASIS REVIEWS

SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo

(2009) Jennifer P. Arbitrario et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

AZD1152 Rapidly and Negatively Affects the Growth and Survival of Human Acute Myeloid Leukemia Cells In vitro and In vivo

(2009) A. Oke et al.   CANCER RESEARCH

A Phase I Dose-Escalation Study of Danusertib (PHA-739358) Administered as a 24-Hour Infusion with and without Granulocyte Colony-Stimulating Factor in a 14-Day Cycle in Patients with Advanced Solid Tumors

(2009) R. B. Cohen et al.   CLINICAL CANCER RESEARCH

Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen

(2009) John McLaughlin et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Phase I Pharmacokinetic and Pharmacodynamic Study of the Aurora Kinase Inhibitor Danusertib in Patients With Advanced or Metastatic Solid Tumors

(2009) Neeltje Steeghs et al.   JOURNAL OF CLINICAL ONCOLOGY

The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma

(2009) Arihiro Aihara et al.   JOURNAL OF HEPATOLOGY

DNA Repair

(2009) Peter Ujhazy et al.   Journal of Thoracic Oncology

Aurora kinase inhibitors synergize with paclitaxel to induce apoptosis in ovarian cancer cells

(2009) Christopher D Scharer et al.   Journal of Translational Medicine

GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models

(2009) M. A. Hardwicke et al.   MOLECULAR CANCER THERAPEUTICS

The Aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model

(2009) E. C. VanderPorten et al.   MOLECULAR CANCER THERAPEUTICS

ZM447439, a Novel Promising Aurora Kinase Inhibitor, Provokes Antiproliferative and Proapoptotic Effects Alone and in Combination with Bio- and Chemotherapeutic Agents in Gastroenteropancreatic Neuroendocrine Tumor Cell Lines

(2009) I. Georgieva et al.   NEUROENDOCRINOLOGY

Identification of genes that confer tumor cell resistance to the Aurora B kinase inhibitor, AZD1152

(2009) J Guo et al.   PHARMACOGENOMICS JOURNAL

Discovery of a potent and selective Aurora kinase inhibitor

(2008) Johan D. Oslob et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate

(2008) Y. Dai et al.   BLOOD

Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I

(2008) A. Gontarewicz et al.   BLOOD

The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma

(2008) Robert P. Evans et al.   BRITISH JOURNAL OF HAEMATOLOGY

Activity of a novel Aurora kinase inhibitor against the T315I mutant form of BCR-ABL:In vitroandin vivostudies

(2008) Daigo Akahane et al.   CANCER SCIENCE

Aurora Kinases as Anticancer Drug Targets

(2008) O. Gautschi et al.   CLINICAL CANCER RESEARCH

Targeting Aurora Kinase with MK-0457 Inhibits Ovarian Cancer Growth

(2008) Y. G. Lin et al.   CLINICAL CANCER RESEARCH

Cotreatment with Vorinostat Enhances Activity of MK-0457 (VX-680) against Acute and Chronic Myelogenous Leukemia Cells

(2008) W. Fiskus et al.   CLINICAL CANCER RESEARCH

Aurora kinases

(2008) Xin Zhang   CURRENT BIOLOGY

280 POSTER Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of MLN8237, a selective Aurora A kinase inhibitor, in the United States

(2008) J. Infante et al.   EJC SUPPLEMENTS

281 POSTER Phase I and pharmacokinetic study of MLN8054, a selective inhibitor of Aurora A kinase

(2008) E. Dees et al.   EJC SUPPLEMENTS

Effects of the Aurora kinase inhibitor VX-680 on anaplastic thyroid cancer-derived cell lines

(2008) Y. Arlot-Bonnemains et al.   ENDOCRINE-RELATED CANCER

Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts

(2008) E. Walsby et al.   HAEMATOLOGICA

Aurora kinase A inhibition and paclitaxel as targeted combination therapy for head and neck squamous cell carcinoma

(2008) Abhijit Mazumdar et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma

(2008) Zhong-Zhe Lin et al.   JOURNAL OF HEPATOLOGY

Fragment-Based Discovery of the Pyrazol-4-yl Urea (AT9283), a Multitargeted Kinase Inhibitor with Potent Aurora Kinase Activity†

(2008) Steven Howard et al.   JOURNAL OF MEDICINAL CHEMISTRY

Aurora A kinase RNAi and small molecule inhibition of Aurora kinases with VE-465 induce apoptotic death in multiple myeloma cells

(2008) Robert Evans et al.   LEUKEMIA & LYMPHOMA

Aurora kinases as targets for cancer therapy

(2007) Giannis Mountzios et al.   CANCER TREATMENT REVIEWS

Aurora kinase small molecule inhibitor destroys mitotic spindle, suppresses cell growth, and induces apoptosis in oral squamous cancer cells

(2007) Caobing Pan et al.   ORAL ONCOLOGY